This report serves to describe the mutational landscape and properties of a given individual set, as well as rank genes and genesets according to mutational significance. MutSig v2.0 was used to generate the results found in this report.
-
Working with individual set: COADREAD-TP
-
Number of patients in set: 223
The input for this pipeline is a set of individuals with the following files associated for each:
-
An annotated .maf file describing the mutations called for the respective individual, and their properties.
-
A .wig file that contains information about the coverage of the sample.
-
MAF used for this analysis:COADREAD-TP.final_analysis_set.maf
-
Blacklist used for this analysis: pancan_mutation_blacklist.v14.hg19.txt
-
Significantly mutated genes (q ≤ 0.1): 42
-
Mutations seen in COSMIC: 738
-
Significantly mutated genes in COSMIC territory: 29
-
Significantly mutated genesets: 35
-
Significantly mutated genesets: (excluding sig. mutated genes):0
-
Read 140 MAFs of type "Broad"
-
Read 87 MAFs of type "Baylor-SOLiD"
-
Total number of mutations in input MAFs: 91943
-
After removing 1369 invalidated mutations: 90574
-
After removing 1176 noncoding mutations: 89398
-
After collapsing adjacent/redundant mutations: 82119
-
Number of mutations before filtering: 82119
-
After removing 847 mutations outside gene set: 81272
-
After removing 343 mutations outside category set: 80929
-
After removing 12 "impossible" mutations in
-
gene-patient-category bins of zero coverage: 79727
Table 1. Get Full Table Table representing breakdown of mutations by type.
type | count |
---|---|
De_novo_Start_InFrame | 20 |
De_novo_Start_OutOfFrame | 156 |
Frame_Shift_Del | 1289 |
Frame_Shift_Ins | 808 |
In_Frame_Del | 166 |
In_Frame_Ins | 26 |
Missense_Mutation | 54063 |
Nonsense_Mutation | 5054 |
Nonstop_Mutation | 36 |
Read-through | 10 |
Silent | 19113 |
Splice_Site | 186 |
Translation_Start_Site | 2 |
Total | 80929 |
Table 2. Get Full Table A breakdown of mutation rates per category discovered for this individual set.
category | n | N | rate | rate_per_mb | relative_rate | exp_ns_s_ratio |
---|---|---|---|---|---|---|
*CpG->T | 20367 | 334435554 | 0.000061 | 61 | 6 | 2.1 |
*Cp(A/C/T)->mut | 21024 | 2765622679 | 7.6e-06 | 7.6 | 0.75 | 3.3 |
A->mut | 12105 | 3006258245 | 4e-06 | 4 | 0.4 | 3.9 |
*CpG->(G/A) | 561 | 334435554 | 1.7e-06 | 1.7 | 0.17 | 2.7 |
indel+null | 7446 | 6106316478 | 1.2e-06 | 1.2 | 0.12 | NaN |
double_null | 304 | 6106316478 | 5e-08 | 0.05 | 0.0049 | NaN |
Total | 61807 | 6106316478 | 1e-05 | 10 | 1 | 3.5 |
The x axis represents the samples. The y axis represents the exons, one row per exon, and they are sorted by average coverage across samples. For exons with exactly the same average coverage, they are sorted next by the %GC of the exon. (The secondary sort is especially useful for the zero-coverage exons at the bottom). If the figure is unpopulated, then full coverage is assumed (e.g. MutSig CV doesn't use WIGs and assumes full coverage).
Figure 1.
![](COADREAD-TP.covplot.png)
Figure 2. Patients counts and rates file used to generate this plot: COADREAD-TP.patients.counts_and_rates.txt
![](COADREAD-TP.bargraphs.png)
The mutation spectrum is depicted in the lego plots below in which the 96 possible mutation types are subdivided into six large blocks, color-coded to reflect the base substitution type. Each large block is further subdivided into the 16 possible pairs of 5' and 3' neighbors, as listed in the 4x4 trinucleotide context legend. The height of each block corresponds to the mutation frequency for that kind of mutation (counts of mutations normalized by the base coverage in a given bin). The shape of the spectrum is a signature for dominant mutational mechanisms in different tumor types.
Figure 3. Get High-res Image SNV Mutation rate lego plot for entire set. Each bin is normalized by base coverage for that bin. Colors represent the six SNV types on the upper right. The three-base context for each mutation is labeled in the 4x4 legend on the lower right. The fractional breakdown of SNV counts is shown in the pie chart on the upper left. If this figure is blank, not enough information was provided in the MAF to generate it.
![](COADREAD-TP.final_analysis_set.maf.mutation_profile.png)
Figure 4. Get High-res Image SNV Mutation rate lego plots for 4 slices of mutation allele fraction (0<=AF<0.1, 0.1<=AF<0.25, 0.25<=AF<0.5, & 0.5<=AF) . The color code and three-base context legends are the same as the previous figure. If this figure is blank, not enough information was provided in the MAF to generate it.
![](COADREAD-TP.final_analysis_set.maf.mutation_profile_AF.png)
Figure 5. Get High-res Image The matrix in the center of the figure represents individual mutations in patient samples, color-coded by type of mutation, for the significantly mutated genes. The rate of synonymous and non-synonymous mutations is displayed at the top of the matrix. The barplot on the left of the matrix shows the number of mutations in each gene. The percentages represent the fraction of tumors with at least one mutation in the specified gene. The barplot to the right of the matrix displays the q-values for the most significantly mutated genes. The purple boxplots below the matrix (only displayed if required columns are present in the provided MAF) represent the distributions of allelic fractions observed in each sample. The plot at the bottom represents the base substitution distribution of individual samples, using the same categories that were used to calculate significance.
![](COADREAD-TP_coMut.png)
Column Descriptions:
-
N = number of sequenced bases in this gene across the individual set
-
n = number of (nonsilent) mutations in this gene across the individual set
-
npat = number of patients (individuals) with at least one nonsilent mutation
-
nsite = number of unique sites having a non-silent mutation
-
nsil = number of silent mutations in this gene across the individual set
-
n1 = number of nonsilent mutations of type: *CpG->T
-
n2 = number of nonsilent mutations of type: *Cp(A/C/T)->mut
-
n3 = number of nonsilent mutations of type: A->mut
-
n4 = number of nonsilent mutations of type: *CpG->(G/A)
-
n5 = number of nonsilent mutations of type: indel+null
-
n6 = number of nonsilent mutations of type: double_null
-
p_classic = p-value for the observed amount of nonsilent mutations being elevated in this gene
-
p_ns_s = p-value for the observed nonsilent/silent ratio being elevated in this gene
-
p_cons = p-value for enrichment of mutations at evolutionarily most-conserved sites in gene
-
p_joint = p-value for clustering + conservation
-
p = p-value (overall)
-
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
Table 3. Get Full Table A Ranked List of Significantly Mutated Genes. Number of significant genes found: 42. Number of genes displayed: 35. Click on a gene name to display its stick figure depicting the distribution of mutations and mutation types across the chosen gene (this feature may not be available for all significant genes).
rank | gene | description | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_classic | p_ns_s | p_clust | p_cons | p_joint | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | FBXW7 | F-box and WD repeat domain containing 7 | 575336 | 45 | 38 | 28 | 2 | 23 | 6 | 5 | 2 | 9 | 0 | <1.00e-15 | 0.0019 | 0.000028 | 0.031 | 0.000021 | <0.000 | <0.000 |
2 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 618889 | 40 | 33 | 21 | 2 | 6 | 20 | 14 | 0 | 0 | 0 | 9.21e-15 | 0.013 | 0.00051 | 0.000022 | 2e-06 | 0.000 | 0.000 |
3 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 130677 | 20 | 20 | 8 | 0 | 2 | 14 | 4 | 0 | 0 | 0 | 7.33e-15 | 0.0075 | 0.000014 | 0.12 | 0.000032 | 0.000 | 0.000 |
4 | SMAD4 | SMAD family member 4 | 375807 | 29 | 26 | 22 | 0 | 10 | 6 | 9 | 0 | 3 | 1 | 6.33e-15 | 0.00043 | 0.027 | 0.0011 | 0.00043 | 1.11e-16 | 4.99e-13 |
5 | APC | adenomatous polyposis coli | 1882819 | 187 | 160 | 128 | 4 | 6 | 15 | 11 | 0 | 103 | 52 | 1.89e-15 | 1.3e-09 | 0 | 0.92 | 0 | <1.00e-15 | <2.25e-12 |
6 | TP53 | tumor protein p53 | 266735 | 121 | 119 | 69 | 2 | 47 | 22 | 12 | 2 | 38 | 0 | <1.00e-15 | 1.1e-10 | 0 | 0 | 0 | <1.00e-15 | <2.25e-12 |
7 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 157303 | 96 | 96 | 11 | 0 | 0 | 91 | 4 | 0 | 1 | 0 | <1.00e-15 | 4.8e-07 | 0 | 0.00073 | 0 | <1.00e-15 | <2.25e-12 |
8 | BRAF | v-raf murine sarcoma viral oncogene homolog B1 | 491043 | 23 | 22 | 4 | 0 | 0 | 0 | 23 | 0 | 0 | 0 | 8.35e-12 | 0.0011 | 0 | 0 | 0 | <1.00e-15 | <2.25e-12 |
9 | FAM123B | family with sequence similarity 123B | 639797 | 27 | 25 | 24 | 2 | 1 | 3 | 4 | 0 | 19 | 0 | 1.47e-12 | 0.13 | 0.0046 | 0.76 | 0.012 | 5.90e-13 | 1.18e-09 |
10 | SMAD2 | SMAD family member 2 | 320993 | 16 | 15 | 12 | 1 | 3 | 5 | 3 | 0 | 5 | 0 | 4.55e-11 | 0.12 | 0.0095 | 0.14 | 0.0082 | 1.11e-11 | 2.00e-08 |
11 | TCF7L2 | transcription factor 7-like 2 (T-cell specific, HMG-box) | 399291 | 20 | 18 | 18 | 4 | 5 | 5 | 3 | 0 | 7 | 0 | 5.41e-09 | 0.15 | 0.0099 | 0.17 | 0.015 | 1.99e-09 | 3.26e-06 |
12 | KRTAP5-5 | keratin associated protein 5-5 | 119310 | 4 | 4 | 1 | 1 | 0 | 0 | 0 | 4 | 0 | 0 | 2.67e-06 | 0.31 | 0.0015 | 0.000048 | 0.000048 | 3.06e-09 | 4.58e-06 |
13 | ACVR1B | activin A receptor, type IB | 338041 | 15 | 14 | 15 | 0 | 4 | 7 | 2 | 0 | 2 | 0 | 1.55e-07 | 0.014 | 0.066 | 0.00044 | 0.0014 | 5.23e-09 | 7.23e-06 |
14 | TNFRSF10C | tumor necrosis factor receptor superfamily, member 10c, decoy without an intracellular domain | 166486 | 6 | 6 | 2 | 0 | 0 | 6 | 0 | 0 | 0 | 0 | 8.46e-05 | 0.24 | 1e-05 | 1 | 0.000053 | 9.14e-08 | 0.000117 |
15 | KIAA1804 | 530272 | 18 | 15 | 16 | 0 | 8 | 7 | 1 | 0 | 2 | 0 | 1.87e-06 | 0.007 | 0.0054 | 0.011 | 0.0047 | 1.70e-07 | 0.000204 | |
16 | MAP2K4 | mitogen-activated protein kinase kinase 4 | 245036 | 11 | 11 | 10 | 1 | 3 | 4 | 2 | 0 | 2 | 0 | 4.05e-07 | 0.24 | 0.047 | 0.046 | 0.031 | 2.43e-07 | 0.000273 |
17 | PCBP1 | poly(rC) binding protein 1 | 175969 | 6 | 6 | 3 | 0 | 0 | 0 | 6 | 0 | 0 | 0 | 0.000415 | 0.33 | 0.0022 | 0.0025 | 0.000077 | 5.85e-07 | 0.000618 |
18 | SOX9 | SRY (sex determining region Y)-box 9 (campomelic dysplasia, autosomal sex-reversal) | 256394 | 10 | 10 | 10 | 0 | 0 | 0 | 1 | 0 | 8 | 1 | 1.21e-06 | 0.48 | 0.038 | 0.44 | 0.086 | 1.77e-06 | 0.00176 |
19 | CCDC160 | coiled-coil domain containing 160 | 85540 | 9 | 7 | 9 | 0 | 0 | 4 | 0 | 1 | 3 | 1 | 6.04e-07 | 0.21 | 0.81 | 0.32 | 0.64 | 6.12e-06 | 0.00579 |
20 | CPXCR1 | CPX chromosome region, candidate 1 | 185655 | 10 | 9 | 10 | 1 | 2 | 5 | 2 | 0 | 1 | 0 | 1.21e-06 | 0.39 | 0.95 | 0.16 | 0.35 | 6.59e-06 | 0.00593 |
21 | CTNNB1 | catenin (cadherin-associated protein), beta 1, 88kDa | 526300 | 12 | 11 | 12 | 0 | 3 | 4 | 3 | 1 | 1 | 0 | 3.93e-06 | 0.075 | 0.24 | 0.96 | 0.34 | 1.92e-05 | 0.0159 |
22 | CDH2 | cadherin 2, type 1, N-cadherin (neuronal) | 602675 | 22 | 16 | 21 | 0 | 3 | 15 | 3 | 1 | 0 | 0 | 1.10e-05 | 0.0041 | 0.063 | 0.53 | 0.12 | 1.95e-05 | 0.0159 |
23 | DKK2 | dickkopf homolog 2 (Xenopus laevis) | 175823 | 6 | 6 | 5 | 1 | 6 | 0 | 0 | 0 | 0 | 0 | 0.00416 | 0.35 | 0.0012 | 0.11 | 0.00058 | 3.34e-05 | 0.0261 |
24 | ACVR2A | activin A receptor, type IIA | 352856 | 10 | 9 | 9 | 1 | 0 | 0 | 4 | 0 | 5 | 1 | 0.000261 | 0.49 | 0.081 | 0.0093 | 0.011 | 4.02e-05 | 0.0293 |
25 | WBSCR17 | Williams-Beuren syndrome chromosome region 17 | 398799 | 19 | 19 | 18 | 3 | 10 | 5 | 1 | 0 | 3 | 0 | 1.73e-05 | 0.05 | 0.09 | 0.68 | 0.17 | 4.09e-05 | 0.0293 |
26 | PTEN | phosphatase and tensin homolog (mutated in multiple advanced cancers 1) | 259135 | 10 | 7 | 8 | 1 | 3 | 2 | 1 | 0 | 3 | 1 | 0.000495 | 0.36 | 0.067 | 0.0048 | 0.0062 | 4.23e-05 | 0.0293 |
27 | PRIM2 | primase, DNA, polypeptide 2 (58kDa) | 210700 | 9 | 8 | 8 | 1 | 0 | 1 | 3 | 0 | 5 | 0 | 2.81e-05 | 0.63 | 0.059 | 0.52 | 0.12 | 4.54e-05 | 0.0302 |
28 | UBE2NL | ubiquitin-conjugating enzyme E2N-like | 102889 | 7 | 7 | 6 | 1 | 2 | 4 | 0 | 1 | 0 | 0 | 1.65e-05 | 0.51 | 0.12 | 0.92 | 0.24 | 5.33e-05 | 0.0342 |
29 | GPC6 | glypican 6 | 370380 | 10 | 10 | 9 | 0 | 5 | 4 | 1 | 0 | 0 | 0 | 5.15e-05 | 0.046 | 0.5 | 0.027 | 0.095 | 6.46e-05 | 0.0400 |
30 | DKK4 | dickkopf homolog 4 (Xenopus laevis) | 152450 | 7 | 7 | 6 | 0 | 3 | 2 | 2 | 0 | 0 | 0 | 0.000150 | 0.16 | 0.058 | 0.17 | 0.042 | 8.17e-05 | 0.0459 |
31 | OR2M4 | olfactory receptor, family 2, subfamily M, member 4 | 209326 | 8 | 8 | 8 | 0 | 3 | 1 | 2 | 0 | 2 | 0 | 5.86e-05 | 0.13 | 0.47 | 0.028 | 0.11 | 8.29e-05 | 0.0459 |
32 | OTOL1 | otolin 1 | 178220 | 8 | 8 | 7 | 0 | 3 | 3 | 1 | 0 | 1 | 0 | 9.36e-06 | 0.1 | 0.72 | 0.34 | 0.69 | 8.37e-05 | 0.0459 |
33 | MGC26647 | chromosome 7 open reading frame 62 | 169132 | 7 | 7 | 7 | 0 | 1 | 2 | 1 | 0 | 3 | 0 | 3.41e-05 | 0.26 | 0.1 | 0.76 | 0.19 | 8.42e-05 | 0.0459 |
34 | ELF3 | E74-like factor 3 (ets domain transcription factor, epithelial-specific ) | 238076 | 6 | 6 | 5 | 0 | 0 | 0 | 1 | 0 | 5 | 0 | 0.000677 | 0.65 | 0.0059 | 0.31 | 0.011 | 9.55e-05 | 0.0505 |
35 | GGT1 | gamma-glutamyltransferase 1 | 245448 | 3 | 3 | 1 | 1 | 0 | 3 | 0 | 0 | 0 | 0 | 0.438 | 0.59 | 0.000091 | 0.000019 | 0.000018 | 0.000101 | 0.0516 |
In this analysis, COSMIC is used as a filter to increase power by restricting the territory of each gene. Cosmic version: v48.
Table 4. Get Full Table Significantly mutated genes (COSMIC territory only). To access the database please go to: COSMIC. Number of significant genes found: 29. Number of genes displayed: 10
rank | gene | description | n | cos | n_cos | N_cos | cos_ev | p | q |
---|---|---|---|---|---|---|---|---|---|
1 | APC | adenomatous polyposis coli | 187 | 839 | 137 | 187097 | 2584 | 0 | 0 |
2 | TP53 | tumor protein p53 | 121 | 824 | 121 | 183752 | 44631 | 0 | 0 |
3 | ERBB3 | v-erb-b2 erythroblastic leukemia viral oncogene homolog 3 (avian) | 14 | 6 | 6 | 1338 | 6 | 5.8e-14 | 8.8e-11 |
4 | NRAS | neuroblastoma RAS viral (v-ras) oncogene homolog | 20 | 33 | 18 | 7359 | 17998 | 2.6e-13 | 2.9e-10 |
5 | KRAS | v-Ki-ras2 Kirsten rat sarcoma viral oncogene homolog | 96 | 52 | 95 | 11596 | 1013913 | 3.9e-13 | 3.5e-10 |
6 | BRAF | v-raf murine sarcoma viral oncogene homolog B1 | 23 | 89 | 20 | 19847 | 287480 | 6.1e-13 | 4e-10 |
7 | FBXW7 | F-box and WD repeat domain containing 7 | 45 | 91 | 31 | 20293 | 1228 | 6.2e-13 | 4e-10 |
8 | SMAD4 | SMAD family member 4 | 29 | 159 | 19 | 35457 | 90 | 9.3e-13 | 5.1e-10 |
9 | KRTAP5-5 | keratin associated protein 5-5 | 4 | 1 | 4 | 223 | 4 | 1.1e-12 | 5.1e-10 |
10 | PIK3CA | phosphoinositide-3-kinase, catalytic, alpha polypeptide | 40 | 220 | 34 | 49060 | 13256 | 1.1e-12 | 5.1e-10 |
Note:
n - number of (nonsilent) mutations in this gene across the individual set.
cos = number of unique mutated sites in this gene in COSMIC
n_cos = overlap between n and cos.
N_cos = number of individuals times cos.
cos_ev = total evidence: number of reports in COSMIC for mutations seen in this gene.
p = p-value for seeing the observed amount of overlap in this gene)
q = q-value, False Discovery Rate (Benjamini-Hochberg procedure)
Table 5. Get Full Table A Ranked List of Significantly Mutated Genesets. (Source: MSigDB GSEA Cannonical Pathway Set).Number of significant genesets found: 35. Number of genesets displayed: 10
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | GSK3PATHWAY | Bacterial lipopolysaccharide activates AKT to promote the survival and activation of macrophages and inhibits Gsk3-beta to promote beta-catenin accumulation in the nucleus. | AKT1, APC, AXIN1, CCND1, CD14, CTNNB1, DVL1, FZD1, GJA1, GNAI1, GSK3B, IRAK1, LBP, LEF1, LY96, MYD88, NFKB1, PDPK1, PIK3CA, PIK3R1, PPP2CA, PRKR, RELA, TIRAP, TLR4, TOLLIP, WNT1 | 26 | AKT1(2), APC(187), AXIN1(2), CD14(1), CTNNB1(12), FZD1(1), GJA1(7), GNAI1(4), GSK3B(8), IRAK1(1), LBP(1), LEF1(4), LY96(2), MYD88(2), NFKB1(6), PDPK1(1), PIK3CA(40), PIK3R1(10), PPP2CA(1), RELA(2), TIRAP(1), TLR4(10), TOLLIP(1), WNT1(1) | 9421260 | 307 | 183 | 228 | 28 | 44 | 50 | 43 | 1 | 115 | 54 | 4.99e-13 | <1.00e-15 | <8.55e-14 |
2 | ST_MYOCYTE_AD_PATHWAY | Cardiac myocytes have a variety of adrenergic receptors that induce subtype-specific signaling effects. | ADRB1, AKT1, APC, ASAH1, BF, CAMP, CAV3, DAG1, DLG4, EPHB2, GAS, GNAI1, GNAQ, HTATIP, ITPR1, ITPR2, ITPR3, KCNJ3, KCNJ5, KCNJ9, MAPK1, PITX2, PLB, PTX1, PTX3, RAC1, RHO, RYR1 | 23 | ADRB1(3), AKT1(2), APC(187), ASAH1(3), CAV3(3), DAG1(5), DLG4(3), EPHB2(8), GNAI1(4), GNAQ(4), ITPR1(19), ITPR2(18), ITPR3(12), KCNJ3(6), KCNJ5(4), KCNJ9(3), MAPK1(2), PITX2(2), PTX3(2), RHO(3), RYR1(25) | 14036969 | 318 | 180 | 258 | 58 | 69 | 53 | 28 | 0 | 115 | 53 | 4.95e-07 | <1.00e-15 | <8.55e-14 |
3 | TGFBPATHWAY | The TGF-beta receptor responds to ligand binding by activating the SMAD family of transcriptional regulations, commonly blocking cell growth. | APC, CDH1, CREBBP, EP300, MADH2, MADH3, MADH4, MADH7, MADHIP, MAP2K1, MAP3K7, MAP3K7IP1, MAPK3, SKIL, TGFB1, TGFB2, TGFB3, TGFBR1, TGFBR2 | 13 | APC(187), CDH1(5), CREBBP(25), EP300(15), MAP2K1(4), MAP3K7(4), MAPK3(3), SKIL(1), TGFB1(1), TGFB2(9), TGFBR1(9), TGFBR2(7) | 8368983 | 270 | 175 | 210 | 25 | 34 | 35 | 30 | 1 | 118 | 52 | 1.75e-10 | <1.00e-15 | <8.55e-14 |
4 | ATRBRCAPATHWAY | BRCA1 and 2 block cell cycle progression in response to DNA damage and promote double-stranded break repair; mutations induce breast cancer susceptibility. | ATM, ATR, BRCA1, BRCA2, CHEK1, CHEK2, FANCA, FANCC, FANCD2, FANCE, FANCF, FANCG, HUS1, MRE11A, NBS1, RAD1, RAD17, RAD50, RAD51, RAD9A, TP53, TREX1 | 21 | ATM(37), ATR(17), BRCA1(6), BRCA2(22), CHEK1(1), CHEK2(1), FANCA(7), FANCC(3), FANCD2(11), FANCF(2), FANCG(4), HUS1(1), MRE11A(8), RAD1(1), RAD17(4), RAD50(11), TP53(121), TREX1(2) | 14298275 | 259 | 148 | 206 | 21 | 80 | 75 | 40 | 2 | 60 | 2 | 6.60e-10 | <1.00e-15 | <8.55e-14 |
5 | ATMPATHWAY | The tumor-suppressing protein kinase ATM responds to radiation-induced DNA damage by blocking cell-cycle progression and activating DNA repair. | ABL1, ATM, BRCA1, CDKN1A, CHEK1, CHEK2, GADD45A, JUN, MAPK8, MDM2, MRE11A, NBS1, NFKB1, NFKBIA, RAD50, RAD51, RBBP8, RELA, TP53, TP73 | 19 | ABL1(4), ATM(37), BRCA1(6), CDKN1A(1), CHEK1(1), CHEK2(1), MAPK8(7), MDM2(4), MRE11A(8), NFKB1(6), RAD50(11), RBBP8(2), RELA(2), TP53(121) | 9687085 | 211 | 145 | 158 | 16 | 67 | 58 | 31 | 3 | 50 | 2 | 1.04e-09 | <1.00e-15 | <8.55e-14 |
6 | SA_G1_AND_S_PHASES | Cdk2, 4, and 6 bind cyclin D in G1, while cdk2/cyclin E promotes the G1/S transition. | ARF1, ARF3, CCND1, CDK2, CDK4, CDKN1A, CDKN1B, CDKN2A, CFL1, E2F1, E2F2, MDM2, NXT1, PRB1, TP53 | 15 | CDK2(2), CDK4(3), CDKN1A(1), CDKN1B(3), CDKN2A(1), CFL1(1), E2F2(1), MDM2(4), NXT1(1), PRB1(1), TP53(121) | 2480575 | 139 | 127 | 87 | 7 | 50 | 26 | 18 | 3 | 42 | 0 | 1.61e-10 | <1.00e-15 | <8.55e-14 |
7 | RNAPATHWAY | dsRNA-activated protein kinase phosphorylates elF2a, which generally inhibits translation, and activates NF-kB to provoke inflammation. | CHUK, DNAJC3, EIF2S1, EIF2S2, MAP3K14, NFKB1, NFKBIA, PRKR, RELA, TP53 | 9 | CHUK(6), DNAJC3(1), EIF2S2(1), MAP3K14(3), NFKB1(6), RELA(2), TP53(121) | 3081784 | 140 | 125 | 88 | 9 | 58 | 24 | 16 | 2 | 40 | 0 | 6.41e-08 | <1.00e-15 | <8.55e-14 |
8 | TELPATHWAY | Telomerase is a ribonucleotide protein that adds telomeric repeats to the 3' ends of chromosomes. | AKT1, BCL2, EGFR, G22P1, HSPCA, IGF1R, KRAS2, MYC, POLR2A, PPP2CA, PRKCA, RB1, TEP1, TERF1, TERT, TNKS, TP53, XRCC5 | 15 | AKT1(2), BCL2(1), EGFR(11), IGF1R(8), POLR2A(6), PPP2CA(1), PRKCA(4), RB1(7), TEP1(7), TERF1(1), TERT(2), TNKS(4), TP53(121), XRCC5(6) | 9118297 | 181 | 143 | 129 | 22 | 74 | 38 | 23 | 3 | 42 | 1 | 6.62e-08 | 1.11e-15 | 8.55e-14 |
9 | ST_GRANULE_CELL_SURVIVAL_PATHWAY | The survival and differentiation of granule cells in the brain is controlled by pro-growth PACAP and pro-apoptotic ceramides. | ADPRT, APC, ASAH1, CAMP, CASP3, CERK, CREB1, CREB3, CREB5, CXCL2, DAG1, EPHB2, FOS, GNAQ, IL8RB, ITPKA, ITPKB, JUN, MAP2K4, MAP2K7, MAPK1, MAPK10, MAPK8, MAPK8IP1, MAPK8IP2, MAPK8IP3, MAPK9, PACAP | 25 | APC(187), ASAH1(3), CASP3(2), CERK(1), CREB1(1), CREB3(3), CREB5(4), DAG1(5), EPHB2(8), FOS(1), GNAQ(4), ITPKB(4), MAP2K4(11), MAPK1(2), MAPK10(8), MAPK8(7), MAPK8IP1(2), MAPK8IP3(2), MAPK9(5) | 9092442 | 260 | 170 | 199 | 25 | 26 | 36 | 28 | 2 | 116 | 52 | 1.65e-11 | 1.33e-15 | 9.12e-14 |
10 | ST_WNT_BETA_CATENIN_PATHWAY | Beta-catenin is degraded in the absence of Wnt signaling; when extracellular Wnt binds Frizzled receptors, beta-catenin accumulates in the nucleus and may promote cell survival. | AKT1, AKT2, AKT3, ANKRD6, APC, AXIN1, AXIN2, C22orf2, CER1, CSNK1A1, CTNNB1, DACT1, DKK1, DKK2, DKK3, DKK4, DVL1, FRAT1, FSTL1, GSK3A, GSK3B, IDAX, LAMR1, LRP1, MVP, NKD1, NKD2, PIN1, PSEN1, PTPRA, SENP2, SFRP1, TSHB, WIF1 | 30 | AKT1(2), AKT2(6), AKT3(1), ANKRD6(5), APC(187), AXIN1(2), AXIN2(9), CER1(3), CSNK1A1(2), CTNNB1(12), DACT1(6), DKK1(5), DKK2(6), DKK3(2), DKK4(7), FSTL1(6), GSK3A(2), GSK3B(8), LRP1(17), MVP(4), NKD1(3), NKD2(1), PIN1(1), PSEN1(3), PTPRA(2), SENP2(3), SFRP1(3), TSHB(1), WIF1(2) | 12599173 | 311 | 185 | 249 | 37 | 60 | 43 | 39 | 1 | 116 | 52 | 1.12e-10 | 1.55e-15 | 9.33e-14 |
Table 6. Get Full Table A Ranked List of Significantly Mutated Genesets (Excluding Significantly Mutated Genes). Number of significant genesets found: 0. Number of genesets displayed: 10
rank | geneset | description | genes | N_genes | mut_tally | N | n | npat | nsite | nsil | n1 | n2 | n3 | n4 | n5 | n6 | p_ns_s | p | q |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1 | HSA00472_D_ARGININE_AND_D_ORNITHINE_METABOLISM | Genes involved in D-arginine and D-ornithine metabolism | DAO | 1 | DAO(6) | 239708 | 6 | 5 | 6 | 0 | 4 | 1 | 0 | 0 | 1 | 0 | 0.15 | 0.043 | 1 |
2 | SA_FAS_SIGNALING | The TNF-type receptor Fas induces apoptosis on ligand binding. | BCL2, CASP3, CASP8, CFL1, CFLAR, P11, PDE6D, TNFRSF6, TNFSF6 | 6 | BCL2(1), CASP3(2), CASP8(11), CFL1(1), CFLAR(3), PDE6D(1) | 1235944 | 19 | 17 | 18 | 2 | 3 | 7 | 5 | 0 | 4 | 0 | 0.11 | 0.072 | 1 |
3 | INOSITOL_METABOLISM | ALDH6A1, ALDOA, ALDOB, ALDOC, TPI1 | 5 | ALDH6A1(4), ALDOA(1), ALDOB(5), ALDOC(3), TPI1(1) | 1203129 | 14 | 13 | 14 | 1 | 4 | 7 | 3 | 0 | 0 | 0 | 0.077 | 0.13 | 1 | |
4 | NUCLEOTIDE_GPCRS | ADORA1, ADORA2A, ADORA2B, ADORA3, GPR23, LTB4R, P2RY1, P2RY2, P2RY5, P2RY6 | 8 | ADORA1(8), ADORA2A(5), ADORA2B(1), ADORA3(3), LTB4R(1), P2RY1(6), P2RY2(3), P2RY6(1) | 1769574 | 28 | 20 | 28 | 4 | 12 | 11 | 3 | 1 | 1 | 0 | 0.011 | 0.28 | 1 | |
5 | HSA00902_MONOTERPENOID_BIOSYNTHESIS | Genes involved in monoterpenoid biosynthesis | CYP2C19, CYP2C9 | 2 | CYP2C19(4), CYP2C9(7) | 660768 | 11 | 9 | 11 | 2 | 3 | 3 | 4 | 0 | 1 | 0 | 0.51 | 0.32 | 1 |
6 | CDC25PATHWAY | The protein phosphatase Cdc25 is phosphorylated by Chk1 and activates Cdc2 to stimulate eukaryotic cells into M phase. | ATM, CDC2, CDC25A, CDC25B, CDC25C, CHEK1, MYT1, WEE1, YWHAH | 8 | ATM(37), CDC25A(2), CDC25B(5), CDC25C(4), CHEK1(1), MYT1(13), WEE1(3), YWHAH(1) | 4495368 | 66 | 37 | 64 | 7 | 13 | 30 | 10 | 1 | 10 | 2 | 0.0065 | 0.34 | 1 |
7 | HSA00785_LIPOIC_ACID_METABOLISM | Genes involved in lipoic acid metabolism | LIAS, LIPT1, LOC387787 | 2 | LIAS(4), LIPT1(4) | 492074 | 8 | 6 | 8 | 1 | 0 | 6 | 1 | 0 | 1 | 0 | 0.58 | 0.35 | 1 |
8 | HSA00830_RETINOL_METABOLISM | Genes involved in retinol metabolism | ALDH1A1, ALDH1A2, BCMO1, RDH5 | 4 | ALDH1A1(4), ALDH1A2(6), BCMO1(4), RDH5(1) | 1251009 | 15 | 13 | 15 | 2 | 6 | 4 | 4 | 0 | 1 | 0 | 0.16 | 0.35 | 1 |
9 | HSA00031_INOSITOL_METABOLISM | Genes involved in inositol metabolism | ALDH6A1, TPI1 | 2 | ALDH6A1(4), TPI1(1) | 498985 | 5 | 5 | 5 | 0 | 0 | 2 | 3 | 0 | 0 | 0 | 0.27 | 0.38 | 1 |
10 | ERBB4PATHWAY | ErbB4 (aka HER4) is a receptor tyrosine kinase that binds neuregulins as well as members of the EGF family, which also target EGF receptors. | ADAM17, ERBB4, NRG2, NRG3, PRKCA, PRKCB1, PSEN1 | 6 | ADAM17(7), ERBB4(21), NRG2(6), NRG3(7), PRKCA(4), PSEN1(3) | 2961197 | 48 | 31 | 47 | 9 | 11 | 19 | 9 | 2 | 7 | 0 | 0.074 | 0.43 | 1 |
In brief, we tabulate the number of mutations and the number of covered bases for each gene. The counts are broken down by mutation context category: four context categories that are discovered by MutSig, and one for indel and 'null' mutations, which include indels, nonsense mutations, splice-site mutations, and non-stop (read-through) mutations. For each gene, we calculate the probability of seeing the observed constellation of mutations, i.e. the product P1 x P2 x ... x Pm, or a more extreme one, given the background mutation rates calculated across the dataset. [1]
In addition to the links below, the full results of the analysis summarized in this report can also be downloaded programmatically using firehose_get, or interactively from either the Broad GDAC website or TCGA Data Coordination Center Portal.